Compare Bristol-Myers Squibb Co (BMY) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Marriott International Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while Marriott International Inc trades at $354.75 (market cap $91.14B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MAR | |
|---|---|---|
Market Cap | $129.94B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $402.54 |
52-Week Low | $42.60 | $259.04 |
Enterprise Value | $163.92B | $108.45B |
Dividend Yield | 3.96% | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Marriott International (MAR) trades at $348.44, down 1.55% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $3.19, beating estimates, but revenue growth faces headwinds. Key risks include high debt levels and valuation concerns, while analyst consensus remains positive with a $387.31 price target.
Outlook: MAR's fee-based model and loyalty program drive growth, but elevated P/E of 36.18 and rising debt-to-asset ratio warrant caution. Upside hinges on sustained RevPAR gains and effective cost management amid global economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
